Literature DB >> 91855

Lisuride in Parkinson's disease.

M Schachter, J Blackstock, J P Dick, R J George, C D Marsden, J D Parkes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 91855     DOI： 10.1016/s0140-6736(79)92523-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view.

Authors:  R Horowski
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

2.  Bromocriptine--lisuride cross tolerance.

Authors:  P Giovannini; G Scigliano; M P Grassi; F Carella; E Parati; T Caraceni
Journal:  Ital J Neurol Sci       Date:  1983-04

3.  The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome).

Authors:  A J Lees; R Bannister
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-04       Impact factor: 10.154

4.  Binding of antiparkinsonian ergot derivatives to the dopamine receptor.

Authors:  R L Weir; R E Hruska; E K Silbergeld
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

5.  Activity of a non-hallucinogenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens.

Authors:  J L Marini; B L Jacobs; M H Sheard; M E Trulson
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2009-11-25       Impact factor: 4.530
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.